Sandoz has agreed to pay $450 million to resolve antitrust litigation brought by 43 US states and territories over alleged anti-competitive conduct in the American generic medicines market.
The Swiss drugmaker’s US subsidiary, Sandoz Inc., will pay $400 million over seven years starting in 2027, with a further $50 million going to states that reached earlier settlements. Sandoz confirmed the agreement contains no admission of wrongdoing.
The settlement is the latest step in litigation stretching back to 2016, when Sandoz Inc. and its subsidiary Fougera Pharmaceuticals were named alongside other generic manufacturers in claims brought by state attorneys general alleging price fixing and market allocation of generic drugs sold in the United States.
The states’ claims sit within the broader multidistrict proceedings, In re Generic Pharmaceuticals Pricing Antitrust Litigation, before the US District Court for the Eastern District of Pennsylvania, which has also handled parallel direct-purchaser and end-payer class actions against Sandoz.
Sandoz has already resolved related federal exposure. In 2020, the company reached a deferred prosecution agreement with the US Department of Justice’s Antitrust Division, and in 2021 it settled False Claims Act allegations with the DOJ’s Civil Division, entering into a corporate integrity agreement with the Department of Health and Human Services’ Office of Inspector General.
Those resolutions closed out federal government claims tied to the same underlying conduct, leaving state-level and private claims as the remaining exposure that this settlement, alongside earlier direct-purchaser and end-payer deals, is now working through.
For in-house counsel at pharmaceutical manufacturers, the settlement structure is instructive. Staggering $400 million in payments over seven years, rather than a single lump sum, reflects an increasingly common approach to managing multistate antitrust exposure without disrupting near-term financial guidance.
Sandoz has said the settlements do not affect its 2026 outlook, a framing that compliance and investor-relations teams at other manufacturers facing parallel state-AG scrutiny are likely to study closely.
State attorneys general have shown particular staying power in pharmaceutical pricing enforcement, continuing to pursue claims years after related federal matters closed. With the underlying multidistrict litigation still active against non-settling defendants, law firms advising generic and biosimilar manufacturers should expect state-level antitrust claims to remain a distinct and long-running front, separate from federal resolution, well into the next several years.